Cecilia Brown

DocwireNews

The US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (BLA) for durvalumab (Imfinzi) as a treatment for limited-stage small cell lung cancer (LS-SCLC) and granted it priority review, according to an announcement from AstraZeneca.The supplemental BLA is based on the <a href="https://www.docwirenews.com/post/phase-3-adriatic-trial-results-show-survival-benefit-of-durvalumab-in-ls-sclc">phase 3 ADRIATIC trial</a>, which evaluated durvalumab in patients with LS-SCLC whose disease has not progressed following platinum-based concurrent chemoradiotherapy. David R. Spigel, MD, a medical oncologist and the chief scientific officer at Sarah Cannon Research Institute, gave a plenary presentation on the phase 3 ADRIATIC trial during the 2024 American Society of Clinical Oncology Annual Meeting.&ldquo;The ADRIATIC study hit both of its primary end points, both overall survival that was improved with an advance of nearly 2 years&hellip; and progression-free survival was improved with an advance of about 7.4 months,&rdquo; Dr. Spigel told Lung Cancers Today in <a href="https://www.docwirenews.com/post/david-spigel-md-on-how-the-phase-3-adriatic-trial-changes-the-standard-of-care-for-ls-sclc">an interview</a> at the 2024 American Society of Clinical Oncology Annual Meeting. &ldquo;The regimen was safe, and these results will translate into durvalumab being a new standard of care. Patients with [LS-SCLC] who get chemoradiotherapy should then get up to 2 years of durvalumab, a great advance for our patients.&rdquo;The study showed that durvalumab reduced the risk of death by 27% compared with the placebo (overall survival (OS) hazard ratio [HR], 0.73; P=.0104), with an estimated median OS of 55.9 months, nearly 2 years longer than the estimated median OS of 33.4 months in patients receiving the placebo. The 3-year survival rate was 57% in those receiving durvalumab, compared with 48% in those receiving the placebo.The phase 3 ADRIATIC study also showed that durvalumab reduced the risk of disease progression or death by 24% compared with the placebo (progression-free survival [PFS] HR, 0.76; P=.0161).The median PFS was 16.6 months in patients receiving durvalumab, compared with 9.2 months in those receiving the placebo. Study investigators estimate that 46% of patients receiving durvalumab had not experienced disease progression at 2 years, compared with 34% of those receiving the placebo.&ldquo;This Priority Review reinforces the potential of Imfinzi to transform outcomes for patients as the first and only immunotherapy to demonstrate a survival benefit in limited-stage small cell lung cancer,&rdquo; AstraZeneca Executive Vice President of Oncology Research and Development Susan Galbraith said in a statement. &ldquo;There is an urgent need for new treatment options that improve upon the standard of care in this setting, which has not changed in 40 years, and we look forward to working with the FDA to bring Imfinzi to patients as quickly as possible.&rdquo;The safety profile for durvalumab &ldquo;was generally manageable and consistent with the known profile of this medicine,&rdquo; and &ldquo;no new safety signals were observed,&rdquo; officials said in the announcement.The FDA also recently granted Breakthrough Therapy Designation to durvalumab in this setting. The Prescription Drug User Fee Act date, the FDA action date for the regulatory decision, is &ldquo;anticipated during the fourth quarter of 2024,&rdquo; officials said.Source: <a href="https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-granted-priority-review-and-breakthrough-therapy-designation-for-patients-with-limited-stage-small-cell-lung-cancer-in-the-us.html">AstraZeneca</a>

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

FDA Grants Durvalumab Priority Review and Breakthrough Therapy Designation for LS-SCLC

Small Cell Lung Cancer

The US FDA has accepted a supplemental Biologics License Application for durvalumab (Imfinzi) as a treatment for limited-stage small cell lung cancer. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe